


Comparison of laparoscopic and open radical hysterectomy in cervical cancer patients with tumor size ≤ 2 cm

Xu Chen,¹ Na Zhao,² Piaopiao Ye,¹ Jiahua Chen,¹ Xingwei Nan,¹ Hongqin Zhao,^{1,3} Kai Zhou,^{1,3} Yuyang Zhang,^{1,3} Jisen Xue,¹ Haihong Zhou,¹ Huiling Shang,⁴ Hanxiao Zhu,⁵ Van der Merwe Leanne,¹ Xiaojian Yan ^{1,3}

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/ijgc-2019-000994>).

For numbered affiliations see end of article.

Correspondence to

Xiaojian Yan, Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China; yxjbetter2016@hotmail.com

XC and NZ contributed equally.

XC and NZ are joint first authors.

Received 17 October 2019
Revised 4 December 2019
Accepted 19 December 2019
Published Online First
9 April 2020



► <http://dx.doi.org/10.1136/ijgc-2020-001406>



© IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Chen X, Zhao N, Ye P, et al. *Int J Gynecol Cancer* 2020;**30**:564–571.

HIGHLIGHTS

- Laparoscopic radical hysterectomy was associated with worse disease-free survival for stage IB1 cervical cancer patients with tumor size ≤ 2 cm.
- Laparoscopy was an independent poor prognostic factor for disease-free survival with an adjusted hazard ratio of 4.64.
- In patients with non-squamous cell carcinoma or with grade II–III, laparoscopic surgery had a worse disease-free survival compared to the open surgery group.

ABSTRACT

Objective There is recent evidence that demonstrates worse oncologic outcomes associated with minimally invasive radical hysterectomy when compared with open radical hysterectomy, particularly in patients with tumors > 2 cm. The aim of our study was to retrospectively evaluate the oncological outcomes between laparoscopic and open radical hysterectomy in International Federation of Gynecology and Obstetrics (FIGO) 2009 stage IB1 (FIGO 2009) cervical cancer patients with tumor size ≤ 2 cm.

Methods A retrospective review of medical records was performed to identify patients who underwent either laparoscopic or open radical hysterectomy during January 2010 and December 2018. Inclusion criteria were: (1) histologically confirmed cervical cancer including all histological types; (2) FIGO 2009 stage IB1; (3) tumor size ≤ 2 cm (determined by pelvic examination, magnetic resonance imaging or transvaginal ultrasound); (4) had undergone radical hysterectomy (type II or III) with pelvic and/or para-aortic lymphadenectomy as primary surgical treatment; (5) had follow-up information. Patients with FIGO 2009 stage IA1 or IA2, tumor size > 2 cm, or who received neo-adjuvant chemotherapy before surgery, those with cervical cancer incidentally found after simple hysterectomy, or with insufficient data were excluded. Concurrent comparison between the laparoscopic and open cohorts was made for disease-free survival and overall survival.

Results A total of 325 cervical cancer patients were included; of these, 129 patients underwent laparoscopic surgery and 196 patients had open surgery. The median follow-up times were 51.8 months (range 2–115) for laparoscopic surgery and 49.5 months (range 3–108) for open surgery. Patients in the laparoscopic group had significantly worse 5 year disease-free survival than those in the open group (90.4% vs 97.7%; $p=0.02$). There was no significant difference in 5 year overall survival between groups (96.9% vs 99.4%, $p=0.33$). The Cox proportional hazards regression analysis indicated that laparoscopic surgery was associated with lower disease-free survival

compared with open surgery (adjusted hazard ratio 4.64, 95% CI 1.26 to 17.06; $p=0.02$). In patients with non-squamous cell carcinoma or with grade II–III, laparoscopic surgery had a significantly worse 5 year disease-free survival compared with the open surgery group (74% vs 100%, $p=0.01$, and 88.8% vs 98.0%, $p=0.02$, respectively).

Conclusion Laparoscopic radical hysterectomy was associated with worse disease-free survival for stage IB1 (FIGO 2009) cervical cancer patients with tumor size ≤ 2 cm compared with open radical hysterectomy. Further studies may shed additional light on the impact of minimally invasive surgery in this low-risk patient population.

INTRODUCTION

Cervical cancer is the fourth most commonly diagnosed cancer and the leading cause of cancer death among women in the world.¹ For patients with early-stage cervical cancer who do not wish to preserve fertility, radical hysterectomy with pelvic lymphadenectomy remains the standard treatment. A series of retrospective studies^{2–8} suggested that laparoscopic surgery and open surgery had comparable oncologic outcomes, with less perioperative complications in laparoscopic surgery. Based on these studies, minimally invasive radical hysterectomy became the standard of care for early-stage cervical cancer in centers with technical resources and trained specialists.

However, a recent prospective, randomized, international multicenter, phase III trial, the Laparoscopic Approach to Cervical Cancer (LACC) trial, suggested that minimally invasive surgery was associated with an unexpectedly higher rate of recurrence and a worse disease-free survival rate when compared with open surgery in patients with stage IA1 (lymphovascular invasion) to IB1 cervical cancer.⁹ In addition, a

retrospective study encompassing 2461 patients from the National Cancer Database (NCDB) also showed a higher risk of death in the minimally invasive group than the open surgery group.¹⁰ These two studies have led to a change in the National Comprehensive Cancer Network (NCCN) guidelines (version 3, 2019).¹¹ The current NCCN guidelines and European Society of Gynaecological Oncology (ESGO)¹² guidelines recommendation is for open radical hysterectomy as the standard surgical approach for early-stage cervical cancer.

Subsequently, a number of retrospective studies have confirmed the inferior oncologic outcomes of laparoscopic surgery, especially in patients with International Federation of Gynecology and Obstetrics (FIGO) 2009 stage IB1 with tumor size 2–4 cm.^{13–14} However, there is great dispute over whether laparoscopic surgery is safe for patients with tumor size ≤ 2 cm. Therefore, we aimed to compare the oncological outcomes between laparoscopic radical hysterectomy and open radical hysterectomy in patients with stage IB1 and tumor size ≤ 2 cm.

METHODS

A total of 744 cervical cancer patients with stage IB1 who underwent laparoscopic radical hysterectomy or open radical hysterectomy from January 2010 to December 2018 from three institutions were included. Our study was approved by the institutional review boards of each institution. Patients were included for analysis if they met the following criteria: (1) histologically confirmed cervical cancer including all histological types; (2) FIGO 2009 stage IB1; (3) tumor size ≤ 2 cm (determined by pelvic examination, magnetic resonance imaging (MRI) or transvaginal ultrasound); (4) had undergone radical hysterectomy (type II or III radical hysterectomy and pelvic and/or para-aortic lymphadenectomy) as primary surgical treatment; (5) had follow-up information. Patients with FIGO 2009 stage IA1 or IA2, tumor size > 2 cm, or who received neo-adjuvant chemotherapy before surgery, those with cervical cancer incidentally found after simple hysterectomy, or with insufficient data were excluded. The final analysis included 325 patients who met the eligibility criteria: 244 patients from the First Affiliated Hospital of Wenzhou Medical University, 39 patients from the First People's Hospital of Foshan, and 42 patients from the Taizhou Hospital of Zhejiang Province.

Adjuvant treatment was indicated after radical hysterectomy if any of the pathologic risk factors identified below were noted. Post-operative radio-chemotherapy was recommended for patients with positive pelvic nodes, positive surgical margin, or positive parametrium. In addition to high-risk factors, radiotherapy \pm chemotherapy was also recommended for patients who had a stromal invasion $> 2/3$ and lymphovascular space invasion, or patients with stromal invasion $1/3$ – $2/3$, lymphovascular space invasion, and tumor size equal to 2 cm. Chemotherapy was recommended for patients who had grade III and tumor size equal to 2 cm.

We used Student's t-test and Mann-Whitney U test to compare continuous variables and Pearson's χ^2 test or Fisher's exact test to compare categorical variables. We presented categorical variables as frequency (percentage). Analyses of survival curves were performed by the Life Table method, and comparisons were made by the Kaplan-Meier methods with log-rank test, with calculation

of a hazard ratio (HR), an accompanying 95% confidence interval (95% CI), and a p value. In multivariate analyses, we calculated HRs and 95% CIs using Cox proportional hazards regression models. All p values were two-sided, and we considered values of $p < 0.05$ to be statistically significant. Statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) statistical software (version 23.0; SPSS Inc, Chicago, IL)

RESULTS

A total of 325 patients with final pathology confirmed tumor size ≤ 2 cm were included for analysis, after excluding 30 patients who were lost to follow-up (18 in the open surgery group and 12 in the laparoscopy group). The evaluation of tumor size was combined with pelvic examination, transvaginal ultrasound and/or MRI. The MRI and pathological measurements indicated no significant difference between the mean maximal tumor diameters (0.92 ± 0.81 cm vs 0.95 ± 0.75 cm; $p = 0.91$). However, there were differences in pelvic examination and ultrasound compared with pathological measurements ($p < 0.001$). The accuracy was estimated by the degree of agreement with a difference of 0.3, 0.5, or 1.0 cm. Based on pathological measurements, MRI seems to have a higher accuracy than pelvic examination and ultrasound (online supplementary table S1). Of these patients, 129 patients underwent laparoscopic surgery and 196 patients underwent open surgery (Table 1). The patients undergoing laparoscopic surgery were more likely to be younger, have a lower rate of lymph node metastasis, and exhibit a lower level of serum squamous cell carcinoma antigen compared with those who underwent open surgery ($p < 0.05$) (Table 1). There were no significant differences between the two groups for histologic type, grade, lymphovascular invasion, depth of invasion, or parametrial involvement (Table 1).

The median follow-up times were 51.8 months (range; 2–115) for laparoscopic surgery and 49.5 months (range; 3–108) for open surgery. A total of seven deaths occurred, four in the laparoscopic group and three in the open surgery group. There was no significant difference in 5 year overall survival between the groups (96.9% vs 99.4%; $p = 0.33$). However, patients in the laparoscopic group had significantly worse 5 year disease-free survival than those in the open surgery group (90.4% vs 97.7%; $p = 0.02$). Patients who underwent open surgery and laparoscopic surgery had recurrence rates of 2.3% and 9.6%, respectively (Figure 1).

We compared the survival outcomes between the open surgery group and the laparoscopic group according to histologic type and grade (Figure 2). In patients with squamous cell carcinoma, the disease-free survival and overall survival were all similar between the two groups ($p = 0.28$ and $p = 0.56$, respectively) (Figure 2A&B). In patients with non-squamous cell carcinoma, the laparoscopic group had a significantly worse 5 year disease-free survival compared with the open surgery group (74% vs 100%; $p = 0.01$) (Figure 2C), and worse 5 year overall survival (81% vs 100%; $p = 0.04$) (Figure 2D). In patients with grade I, disease-free survival and overall survival were similar between the two groups ($p = 0.31$ and $p = 0.43$, respectively) (Figure 2E&F). In patients with grade II or grade III, the laparoscopic group showed significantly worse 5 year disease-free survival compared with the open surgery group (88.8% vs 98.0%; $p = 0.02$), whereas 5-year overall survival

Table 1 Clinicopathologic characteristics of patients with FIGO stage IB1 and tumor size ≤ 2 cm

Characteristics	All (n=325, %)	Open surgery group (n=196, %)	Laparoscopy group (n=129, %)	P value
Age, years				
Mean \pm SD	50.74 \pm 9.94	51.69 \pm 10.25	49.29 \pm 9.31	0.033
BMI, kg/m ²				
Mean \pm SD	22.98 \pm 3.19	22.98 \pm 3.14	22.99 \pm 3.29	0.978
Histologic type				0.624
Squamous cell carcinoma	268 (82.46)	165 (84.18)	103 (79.84)	
Adenocarcinoma	42 (12.92)	23 (11.73)	19 (14.73)	
Adenosquamous	10 (3.08)	6 (3.06)	4 (3.10)	
Others	5 (1.54)	2 (1.02)	3 (2.33)	
Grade				0.111
I	59 (18.15)	34 (17.35)	25 (19.38)	
II	114 (35.08)	60 (30.61)	54 (41.86)	
III	107 (32.92)	71 (36.22)	36 (27.91)	
Not reported	45 (13.85)	31 (15.82)	14 (10.85)	
Preoperative conization or LEEP				0.253
Yes	87 (27.77)	48 (24.49)	39 (30.23)	
No	238 (73.23)	148 (75.51)	90 (69.77)	
LVSI				0.438
Yes	49 (15.08)	32 (16.33)	17 (13.18)	
No	276 (84.92)	164 (83.67)	112 (86.82)	
Invasion depth				0.369
Inner 1/3	201 (61.85)	115 (58.67)	86 (66.67)	
Middle 1/3	62 (19.08)	39 (19.90)	23 (17.83)	
Deep 1/3	42 (12.92)	30 (15.31)	12 (9.30)	
Not reported	20 (6.15)	12 (6.12)	8 (6.20)	
Parametrial involvement				0.416
Yes	1 (0.31)	1 (0.51)	0 (0)	
No	324 (99.69)	195 (99.49)	129 (100)	
Lymph node metastasis				0.024
Yes	12 (3.69)	11 (5.61)	1 (0.78)	
No	313 (96.31)	185 (94.39)	128 (99.22)	
Resection margin				0.416
Positive	1 (0.31)	1 (0.51)	0 (0)	
Negative	324 (99.69)	195 (99.49)	129 (100)	
Serum SCC level, ng/mL				0.017
n	250	172	78	
Mean \pm SD	1.06 \pm 0.87	1.15 \pm 0.92	0.86 \pm 0.69	
Adjuvant treatment				0.386
Yes	97 (29.85)	62 (31.63)	35 (27.13)	
No	228 (70.15)	134 (68.37)	94 (72.87)	
Median follow-up	51.27	49.5	51.8	0.62

BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; LEEP, loop electrosurgical excision procedure.; LVSI, lymphovascular space invasion; SCC, squamous cell carcinoma.




Figure 1 Survival outcomes of laparotomy surgery and laparoscopy surgery in patients with FIGO stage IB1 and tumor size ≤ 2 cm. FIGO, International Federation of Gynecology and Obstetrics.

was similar between the two groups ($p=0.21$) (Figure 2G&H). The Cox proportional hazards regression analysis identified laparoscopy as an independent poor prognostic factor for disease-free survival (adjusted HR 4.64, 95% CI, 1.26 to 17.06; $p=0.02$) (Table 2).

At the end of the follow-up time, 16 patients had a recurrence (11 in the laparoscopic group and five in the open surgery group). Recurrences in patients in the open surgery group were located at the vault ($n=3$), pelvis ($n=1$), and distant metastasis ($n=1$, lung). Recurrences in patients in the laparoscopic group were located at the vault ($n=2$), pelvis ($n=1$), distant metastasis ($n=7$, lung=2, bone=1, liver=1, multi-organ=3), and other ($n=1$) (online supplementary table S2).

DISCUSSION

Our results demonstrated worse disease-free survival in patients with stage IB1 and with tumor size ≤ 2 cm undergoing laparoscopic radical hysterectomy compared with the open radical hysterectomy. These findings are very consistent with those of the LACC trial⁹ and the recent population database analysis¹⁰ published in the *New England Journal of Medicine*. However, in those studies the authors remarked that no specific conclusions could be made regarding patients with tumors ≤ 2 cm given the fact that the studies were not powered to answer this question. In our study, inferior disease-free survival was noted in the laparoscopic group compared with the open surgery group, but there was no significant difference for overall survival. This finding may be secondary to the fact that patients with recurrences in the laparoscopic group could have been salvaged with either chemoradiotherapy or chemotherapy alone.

In the setting of cervical cancer patients with tumor size > 2 cm, there are several studies which confirmed that laparoscopic surgery has a worse survival rate than open surgery. In the large retrospective study from the NCCDB with 3686 cervical cancer cases, Melamed et al¹⁰ reported that minimally invasive surgery

was associated with a higher risk of death than open surgery for patients with tumor size ≥ 2 cm (HR 1.66, 95% CI 1.19 to 2.30). Kim et al¹⁵ studied 593 patients with early-stage cervical cancer and found that cervical cancer patients who underwent minimally invasive surgery had significantly worse progression-free survival than those in the open surgery group with tumor size > 2 cm and ≤ 4 cm ($p=0.044$). In addition, Cusimano et al¹⁴ reported that minimally invasive surgery was associated with a higher rate of recurrence and death compared with the open surgery group in cervical cancer with stage IB1, and that the harm associated with this approach may be independent of surgeon volume.

Cervical cancer with tumor size ≤ 2 cm is considered a low-risk type. There are some studies^{16,17} confirming that patients with stage IB1 and tumor size < 2 cm had a better 5 year overall survival, ranging from 95.2–97%. The better survival led to the update of the 2018 FIGO surgical stage for cervical cancer.¹⁸ However, there was still a debate over those patients with tumor size ≤ 2 cm and whether laparoscopic radical hysterectomy would lead to a poorer survival or not. Interestingly, a number of studies have shown that patients with tumor size ≤ 2 cm who underwent laparoscopic surgery had comparable survival to those undergoing open surgery. Kim et al¹⁹ reported that among the matched patients with tumor size ≤ 2 cm on pre-operative MRI who underwent laparoscopic radical hysterectomy had similar 5 year overall survival (98.6% vs. 96.4%; $p=0.6$) and 3 year progression-free survival (90.0% vs. 93.1%; $p=0.8$) compared with those undergoing open surgery. In another multicentric retrospective study from Italy,²⁰ among patients with tumor ≤ 2 cm, laparoscopy showed disease-free survival superimposable to open surgery (HR 0.56, 95%CI 0.27 to 1.18; $p=0.13$). However, in both of these studies, the median follow-up time of the open surgery group was longer than that of the laparoscopic group (133.4 vs 46.8 months, $p < 0.001$; 76 vs 47 months, $p=0.068$, respectively).

More recently, there have been numerous studies demonstrating that laparoscopic surgery was associated with worse survival




Figure 2 Comparisons of survival outcomes for (A,B) squamous cell carcinoma, (C,D) non-squamous cell carcinoma, (E,F) grade I, and (G,H) grade II-III.

Table 2 Factors associated with disease-free survival in patients with FIGO stage IB1 and tumor size ≤ 2 cm

Characteristics	Univariate analysis			Multivariate analysis		
	HR	95% CI	P value	Adjusted HR	95% CI	P value
Age, years						
<50	1 (Ref)	–	–	1 (Ref)	–	–
≥ 50	1.035	(0.984 to 1.089)	0.178	1.600	(0.501 to 5.112)	0.428
Histology						
SCC	1 (Ref)	–	–	1 (Ref)	–	–
Non-SCC	2.064	(0.717 to 5.944)	0.179	3.114	(0.838 to 11.576)	0.090
Preoperative conization or LEEP						
No	1 (Ref)	–	–	1 (Ref)	–	–
Yes	0.382	(0.087 to 1.682)	0.203	0.211	(0.027 to 1.659)	0.139
Grade						
I	1 (Ref)	–	–	1 (Ref)	–	–
II–III	0.737	(0.202 to 2.686)	0.644	1.031	(0.262 to 4.053)	0.965
Parametrial involvement						
No	1 (Ref)	–	–			
Yes	0.049	(0 to 2.231E+15)	0.878			
Lymph node involvement						
No	1 (Ref)	–	–			
Yes	0.047	(0 to 4325.232)	0.6			
Invasion depth						
<2/3	1 (Ref)	–	–	1 (Ref)	–	–
$\geq 2/3$	0.383	(0.050 to 2.914)	0.354	0.732	(0.085 to 6.326)	0.777
LVSI						
No	1 (Ref)	–	–	1 (Ref)	–	–
Yes	0.827	(0.188 to 3.642)	0.802	2.965	(0.546 to 16.090)	0.208
Adjuvant treatment						
No	1 (Ref)	–	–	1 (Ref)	–	–
Yes	0.512	(0.146 to 1.796)	0.296	0.261	(0.048 to 1.414)	0.119
Surgical approach						
Open surgery	1 (Ref)	–	–	1 (Ref)	–	–
Laparoscopy	3.381	(1.174 to 9.733)	0.024	4.64	(1.26 to 17.06)	0.02

FIGO, International Federation of Gynecology and Obstetrics; LEEP, loop electrosurgical excision procedure.; LVSI, lymphovascular space invasion; Ref, reference; SCC, squamous cell carcinoma.

compared with open surgery for patients with tumor size ≤ 2 cm. First, Odetto et al²¹ included 108 patients with stage IA1 with lymphovascular invasion to IB1 and reported that the recurrence rate in patients with tumor size ≤ 2 cm was 12% (7/58); three of these seven patients relapsed with carcinomatosis, which was higher than that found in the LACC trial (8.4%) including patients with tumor size < 4 cm. Paik et al²² reported that laparoscopic surgery was associated with a lower disease-free survival rate (HR 12.987, 95%CI 1.45 to 116.24; $p=0.003$) than open surgery, but no significant difference was noted in overall survival ($p=0.56$) in patients with tumor size < 2 cm. Uppal et al²³ reported 264 patients with tumors ≤ 2 cm on final pathology, 2/82 (2.4%) recurred in the open radical hysterectomy group and 16/182 (8.8%) in the

minimally invasive group ($p=0.06$). In the risk-adjusted analysis, the minimally invasive group approach was noted to be independently associated with a higher likelihood of recurrence (aHR 6.31, 95% CI 1.24 to 31.9; $p=0.03$). However, a subset of patients with prior conization and no visible tumor before radical hysterectomy had low risk of recurrence with either technique. The authors suggested this group might be an ideal cohort to be studied in future clinical trials. In our study, the 5-year overall survival was 99.4% in the open surgery group and 96.9% in the laparoscopic group ($p=0.33$); however, the laparoscopic group had a significantly lower 5-year disease-free survival compared with the open surgery group ($p=0.016$). Multivariate analysis results also demonstrated that laparoscopic surgery is an independent poor prognostic predictor

Original research

for disease-free survival (HR 4.64, 95% CI 1.26 to 17.06; $p=0.02$). Besides this, the rate of lymph node metastasis was higher in patients who underwent open surgery than in those who had laparoscopic surgery ($p=0.02$). Patients who underwent laparoscopic radical hysterectomy would be predicted to have longer survival than those undergoing open surgery on the basis of the rate of lymph node metastasis. However, this was not the case.

In terms of tumor size measurement, our results also suggest that MRI seems to have higher consistency and accuracy with pathology. Several studies suggested that using MRI to measure tumor size has proven to be more accurate than pelvic examination.^{24–26} However, Lee et al²⁷ reported that for patients with stage IB to II cervical cancer, pelvic examination was superior to MRI or CT in the evaluation of tumor size. The accuracy of different methods for measuring tumor diameter is still controversial.

There are several potential reasons that may account for the inferior survival outcomes of laparoscopic surgery. The use of a uterine manipulator may increase the risk of tumor spillage.²⁸ In addition, the different approaches to handle the vaginal margin might also influence the risk of recurrence. Kong et al²⁸ reported that the recurrence rate was 16.3% in the minimally invasive group with intracorporeal colpotomy, which was higher than that with vaginal colpotomy (5.1%, $p=0.06$), and the rate of a positive surgical margin was higher in the intracorporeal colpotomy group. Meanwhile, the 2 year disease-free survival was 93.7% in the vaginal colpotomy group but 80.8% in the intracorporeal colpotomy group. These findings emphasize the importance of avoiding tumor spillage and diminishing tumor handling during minimally invasive surgery. Some studies have suggested that carbon dioxide (CO₂) could increase the proliferation of cervical cancer cells and cause tumor spillage.^{28–29} Further investigation is warranted to better comprehend the mechanism of inferior oncological outcomes of laparoscopic surgery.

According to these findings, many gynecologic oncologists have modified their approaches. In a retrospective study which evaluated patients through a sequential comparison, Kanao et al³⁰ used the "no-look no-touch" technique in cervical cancer patients with stage IB1 to prevent direct exposure of the cervical cancer to the surgical field by use of a uterine manipulator. Their results showed that there was no significant difference in overall survival, disease-free survival, and loco-regional recurrence rate in the modified laparoscopic group and open surgery group ($p=0.59$, $p=0.19$, and $p=0.57$, respectively). In addition, Kohler et al³¹ reported that the 4.5 year disease-free survival rate was 95.8% and the 4.5 year overall survival rate was 97.8% in early stage patients who underwent vaginally-assisted laparoscopic radical hysterectomy, which could avoid use of a uterine manipulator and spillage of tumor cells, and were similar to the results of open surgery in the LACC trial.⁹ However, if the vaginal cuff created was not completely closed, the tumor cells would be exposed to CO₂ and tumor spillage would still not be avoided. It should also be noted that in that study all patients underwent intraoperative lymph node frozen section, and if these were found to be positive for disease then the patients were excluded from the analysis.

In this study, we found that patients with non-squamous cell carcinoma or with grade II–III, laparoscopic surgery had a significantly worse 5 year disease-free survival compared with the open surgery group. Non-squamous tumors are well known to have worse

survival outcomes compared with squamous cell carcinoma.^{32–33} Therefore, it has been suggested from retrospective studies that poorly differentiated tumors have an adverse prognostic factor for recurrence in cervical cancer.^{34–35} Therefore, it is not difficult to understand that non-squamous carcinoma and high-grade cervical cancers which have an aggressive tumor nature, together with the risk of laparoscopic surgery, will lead to worse survival outcomes. Especially in this study, we only included patients with tumor size ≤ 2 cm. Therefore, the good prognosis of these tumors may mask the adverse effects of surgical approaches during the follow-up period of this study.

The strength of our study is that we conducted research on low-risk early stage cervical cancer patients, especially cervical cancer with FIGO 2009 stage IB1 and tumor size ≤ 2 cm. In addition, our follow-up information is complete, which increases the credibility of our study. Limitations include the retrospective nature of the study with a limited sample size, which might introduce inevitable selection bias and confounders. In addition, we did not have a pathology review of the surgical specimens collected. Lastly, our study does not provide details on the robotic radical hysterectomy approach.

In conclusion, laparoscopic radical hysterectomy was associated with worse oncological outcomes for cervical cancer patients with tumor size ≤ 2 cm compared with open radical hysterectomy. Further studies may shed additional light on the impact of minimally invasive surgery in this low-risk patient population.

Author affiliations

¹Department of Gynecology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

²Department of Gynecology, Wenzhou People's Hospital, Wenzhou, Zhejiang, China

³Center for Uterine Cancer Diagnosis & Therapy Research of Zhejiang Province, Wenzhou, Zhejiang, China

⁴Department of Obstetrics and Gynecology, The First People's Hospital of Foshan, Foshan, Guangdong, China

⁵Department of Gynecology, Taizhou Hospital of Zhejiang Province, Taizhou, China

Acknowledgements The authors thank Qingdong Lin, PhD for providing medical writing support. The authors also thank Jingwei Zheng, PhD for providing statistical processing support.

Contributors XC, NZ and XY: Conceptualization, data curation, writing original draft preparation, manuscript preparation, supervision. PP-Y, J-HC, XW-N: Data Collection. HQZ, KZ, Y-YZ and H-LS: Data analysis and interpretation. LVDM and H-HZ: Statistical analysis. All authors read and approved the final manuscript.

Funding This work was supported by funds from the National Natural Science Foundation of China No. 81503293 (XY), the Technology Development Funds of Wenzhou City No. Y20190014 (XY), and the Zhejiang Provincial Natural Science Foundation of China No. LY19H160028 (HZ).

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. The data of figures and tables can be published.

ORCID iD

Xiaojian Yan <http://orcid.org/0000-0002-5306-4484>

REFERENCES

- 1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin* 2019;69:7–34.
- 2 Nam J-H, Park J-Y, Kim D-Y, et al. Laparoscopic versus open radical hysterectomy in early-stage cervical cancer: long-term survival outcomes in a matched cohort study. *Ann Oncol* 2012;23:903–11.

- 3 Toptas T, Simsek T. Total laparoscopic versus open radical hysterectomy in stage IA2-IB1 cervical cancer: disease recurrence and survival comparison. *J Laparosc Adv Surg Tech A* 2014;24:373–8.
- 4 Wang W, Chu HJ, Shang CL, *et al.* Long-term oncological outcomes after laparoscopic versus abdominal radical hysterectomy in stage IA2 to IIA2 cervical cancer: a matched cohort study. *Int J Gynecol Cancer* 2016;26:1264–73.
- 5 Wang Y-zhou, Deng L, Xu H-cheng, *et al.* Laparoscopy versus laparotomy for the management of early stage cervical cancer. *BMC Cancer* 2015;15:928.
- 6 Zhu T, Chen X, Zhu J, *et al.* Surgical and pathological outcomes of laparoscopic versus abdominal radical hysterectomy with pelvic lymphadenectomy and/or para-aortic lymph node sampling for bulky early-stage cervical cancer. *Int J Gynecol Cancer* 2017;27:1222–7.
- 7 Li X, Li J, Wen H, *et al.* The survival rate and surgical morbidity of abdominal radical trachelectomy versus abdominal radical hysterectomy for stage IB1 cervical cancer. *Ann Surg Oncol* 2016;23:2953–8.
- 8 Park J-Y, Kim D, Suh D-S, *et al.* The role of laparoscopic radical hysterectomy in early-stage adenocarcinoma of the uterine cervix. *Ann Surg Oncol* 2016;23:825–33.
- 9 Ramirez PT, Frumovitz M, Pareja R, *et al.* Minimally invasive versus abdominal radical hysterectomy for cervical cancer. *N Engl J Med* 2018;379:1895–904.
- 10 Melamed A, Margul DJ, Chen L, *et al.* Survival after minimally invasive radical hysterectomy for early-stage cervical cancer. *N Engl J Med* 2018;379:1905–14.
- 11 Koh W-J, Abu-Rustum NR, Bean S, *et al.* Cervical cancer, version 3.2019, NCCN clinical practice guidelines in oncology. *J Natl Compr Canc Netw* 2019;17:64–84.
- 12 Querleu D, Cibula D, Concin N, *et al.* Laparoscopic radical hysterectomy: an ESGO statement. European Society of Gynaecological Oncology (ESGO). Available: <https://www.esgo.org/explore/council/laparoscopic-radical-hysterectomy-an-esgo-statement/> [Accessed 27 May 2019].
- 13 Doo DW, Kirkland CT, Griswold LH, *et al.* Comparative outcomes between robotic and abdominal radical hysterectomy for IB1 cervical cancer: results from a single high volume institution. *Gynecol Oncol* 2019;153:242–7.
- 14 Cusimano MC, Baxter NN, Gien LT, *et al.* Impact of surgical approach on oncologic outcomes in women undergoing radical hysterectomy for cervical cancer. *Am J Obstet Gynecol* 2019.
- 15 Kim SI, Cho JH, Seol A, *et al.* Comparison of survival outcomes between minimally invasive surgery and conventional open surgery for radical hysterectomy as primary treatment in patients with stage IB1–IIA2 cervical cancer. *Gynecol Oncol* 2019;153:3–12.
- 16 Ayhan A, Aslan K, Bulut AN, *et al.* Is the revised 2018 FIGO staging system for cervical cancer more prognostic than the 2009 FIGO staging system for women previously staged as Ib disease? *Eur J Obstet Gynecol Reprod Biol* 2019;240:209–14.
- 17 Matsuo K, Machida H, Mandelbaum RS, *et al.* Validation of the 2018 FIGO cervical cancer staging system. *Gynecol Oncol* 2019;152:87–93.
- 18 Bhatla N, Aoki D, Sharma DN, *et al.* Cancer of the cervix uteri. *Int J Gynecol Obstet* 2018;143:22–36.
- 19 Kim SI, Lee M, Lee S, *et al.* Impact of laparoscopic radical hysterectomy on survival outcome in patients with FIGO stage Ib cervical cancer: a matching study of two institutional hospitals in Korea. *Gynecol Oncol* 2019;155:75–82.
- 20 Pedone Anchora L, Turco LC, Bizzarri N, *et al.* How to select early-stage cervical cancer patients still suitable for laparoscopic radical hysterectomy: a Propensity-Matched study. *Ann Surg Oncol* 2020. doi:10.1245/s10434-019-08162-5. [Epub ahead of print: 02 Jan 2020].
- 21 Odetto D, Puga MC, Saadi J, *et al.* Minimally invasive radical hysterectomy: an analysis of oncologic outcomes from hospital Italiano (Argentina). *Int J Gynecol Cancer* 2019;29:863–8.
- 22 Paik ES, Lim MC, Kim M-H, *et al.* Comparison of laparoscopic and abdominal radical hysterectomy in early stage cervical cancer patients without adjuvant treatment: ancillary analysis of a Korean Gynecologic Oncology Group study (KGOG 1028). *Gynecol Oncol* 2019;154:547–53.
- 23 Uppal S, Gehrig P, Vetter MH, *et al.* Recurrence rates in cervical cancer patients treated with abdominal versus minimally invasive radical hysterectomy: a multi-institutional analysis of 700 cases. *Am J Clin* 2019.
- 24 Mitchell DG, Snyder B, Coakley F, *et al.* Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 intergroup study. *JCO* 2006;24:5687–94.
- 25 Tanaka YO, Okada S, Satoh T, *et al.* Uterine cervical cancer volumetry using T2- and diffusion-weighted MR images in patients treated by primary surgery and neoadjuvant chemotherapy. *Acta radiol* 2016;57:378–83.
- 26 Zhang W, Zhang J, Yang J, *et al.* The role of magnetic resonance imaging in pretreatment evaluation of early-stage cervical cancer. *Int J Gynecol Cancer* 2014;24:1292–8.
- 27 Lee Y-K, Han S-S, Kim JW, *et al.* Value of pelvic examination and imaging modality for the evaluation of tumor size in cervical cancer. *J Gynecol Oncol* 2008;19:108–12.
- 28 Kong T-W, Chang S-J, Piao X, *et al.* Patterns of recurrence and survival after abdominal versus laparoscopic/robotic radical hysterectomy in patients with early cervical cancer. *J Obstet Gynaecol Res* 2016;42:77–86.
- 29 Lin F, Pan L, Li L, *et al.* Effects of a simulated CO2 pneumoperitoneum environment on the proliferation, apoptosis, and metastasis of cervical cancer cells in vitro. *Med Sci Monit* 2014;20:2497–503.
- 30 Kanao H, Matsuo K, Aoki Y, *et al.* Feasibility and outcome of total laparoscopic radical hysterectomy with no-look no-touch technique for FIGO IB1 cervical cancer. *J Gynecol Oncol* 2019;30:e71.
- 31 Köhler C, Hertel H, Herrmann J, *et al.* Laparoscopic radical hysterectomy with transvaginal closure of vaginal cuff - a multicenter analysis. *Int J Gynecol Cancer* 2019;29:845–50.
- 32 Cao L, Wen H, Feng Z, *et al.* Distinctive clinicopathologic characteristics and prognosis for different histologic subtypes of early cervical cancer. *Int J Gynecol Cancer* 2019;29:1244–51.
- 33 Gien LT, Beauchemin M-C, Thomas G. Adenocarcinoma: a unique cervical cancer. *Gynecol Oncol* 2010;116:140–6.
- 34 Eifel PJ, Burke TW, Delclos L, *et al.* Early stage I adenocarcinoma of the uterine cervix: treatment results in patients with tumors \leq 4 cm in diameter. *Gynecol Oncol* 1991;41:199–205.
- 35 Metindir J, Bilir G. Prognostic factors affecting disease-free survival in early-stage cervical cancer patients undergoing radical hysterectomy and pelvic-para-aortic lymphadenectomy. *Eur J Gynaecol Oncol* 2007;28:28–32.